THe aim of the study was to evaluate the activity of epidoxorubicin (EPI) and gemcitabine (GEM) and to define the most effective schedule in human bladder cancer cells. Our findings show that the efficacy of the EPI and GEM combination is highly schedule dependent and indicate that the most active scheme is EPI followed by GEM, which is currently being validated in an ongoing intravesical Phase-II clinical protocol.
Schedule-dependent cytotoxic interaction between Epidoxorubicin and Gemcitabine in human bladder cancer cells in vitro / ZOLI W; RICOTTI L; TESEI A; ULIVI P; GASPERI CAMPANI A.; FABBRI F; GUNELLI R; FRASSINETI GL; AMADORI D. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - STAMPA. - 10:(2004), pp. 1500-1507. [10.1158/1078-0432.CCR-1107-03]
Schedule-dependent cytotoxic interaction between Epidoxorubicin and Gemcitabine in human bladder cancer cells in vitro.
TESEI, ANNA;ULIVI, PAOLA;GASPERI CAMPANI, ANNA;
2004
Abstract
THe aim of the study was to evaluate the activity of epidoxorubicin (EPI) and gemcitabine (GEM) and to define the most effective schedule in human bladder cancer cells. Our findings show that the efficacy of the EPI and GEM combination is highly schedule dependent and indicate that the most active scheme is EPI followed by GEM, which is currently being validated in an ongoing intravesical Phase-II clinical protocol.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
